WELIREG 40 MG — DIN 02528908
BELZUTIFAN : 40 MG · MERCK CANADA INC · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is WELIREG?
WELIREG 40 MG contains BELZUTIFAN : 40 MG. It is listed in the Health Canada Drug Product Database under DIN 02528908, held by MERCK CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 01-Sep-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is WELIREG used for?
WELIREG® (belzutifan) is indicated for: Von Hippel-Lindau (VHL) disease WELIREG® is indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated non-metastatic renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or non-metastatic pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery. Renal Cell Carcinoma WELIREG® is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Belzutifan cost around the world?
Belzutifan is listed on 6 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Greece publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United Arab Emirates | public | 1 | 1 | AED███.██ |
| Australia | ex-manufacturer | 1 | 1 | AUD███.██ |
| Bahrain | retail (max) | 1 | 1 | BHD███.██ |
| Greece | producer price (ex-factory) | 1 | 1 | EUR███.██ |
| Norway | max AUP (pharmacy retail) | 1 | 1 | NOK███.██ |
| Saudi Arabia | public | 1 | 1 | SAR███.██ |
6 pack listings across 6 brand entries and 5 price bases, refreshed 08 Sep 2026. Ranges span every Belzutifan pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 40 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | 40 mg tablets of WELIREG®: blue, oval, film-coated tablet with “177” on one side. Available in bottle of 90 tablets with desiccant and blisters of 90 tablets (3 cartons of 30 tablets inside of a larger, master carton). |
| Storage | Store WELIREG® at room temperature, between 15°C to 30°C. Keep out of reach and sight of children. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Belzutifan |
|---|---|
| ATC code | L01XX74 |
| AHFS class | 08:12.07.08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02528908 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2528908 |
| Brand name | WELIREG |
| Generic / active ingredient | BELZUTIFAN : 40 MG |
| Market authorization holder | MERCK CANADA INC |
| Health Canada schedule | Prescription |
| ATC code | L01XX74 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L01XX |
| Current status | MARKETED |
| Status date | 01-Sep-2022 |
| Original market date | 2024-08-19 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
The recommended dose of WELIREG® is 120 mg (three 40 mg tablets) administered orally once daily, with or without food. Tablets should be swallowed whole. Treatment should continue until disease progression or unacceptable toxicity occurs. Dose Modification Guidelines for adverse reactions: - First dose reduction: WELIREG® 80 mg orally once daily - Second dose reduction: WELIREG® 40 mg orally once daily - Third dose reduction: Permanently discontinue For Anemia (Grade 3 or transfusion indicated): - Withhold until resolved to ≤ Grade 2. - Resume at the same or reduced dose (reduce by 40 mg) or discontinue; consider discontinuing depending on the severity and persistence of anemia. For Anemia (Grade 4): - Withhold until resolved to ≤ Grade 2. - Resume at a reduced dose (reduce by 40 mg) or permanently discontinue upon recurrence of Grade 4. For Hypoxia (Grade 2): - Consider whether to continue or withhold until resolved. - If withheld, consider resuming at a reduced dose depending on severity and persistence of hypoxia. For Hypoxia (Grade 3): - Withhold until resolved. - Resume at reduced dose (reduce by 40 mg) or discontinue depending on the severity and persistence of hypoxia. For Hypoxia (Grade 4 or recurrent symptomatic hypoxia): - Permanently discontinue. For Other Adverse Reactions (Grade 3): - Withhold dosing until symptoms improve to ≤ Grade 2. - Consider resuming at a reduced dose (reduce by 40 mg). - Permanently discontinue WELIREG® if Grade 3 adverse reaction recurs. For Other Adverse Reactions (Grade 4): - Permanently discontinue. Missed Dose: If a dose is missed, it can be taken as soon as possible on the same day. The regular daily dose schedule should be resumed the next day. Extra tablets should not be taken to make up for the missed dose. If vomiting occurs any time after taking WELIREG®, the dose should not be retaken. The next dose should be taken the next day.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
WELIREG® is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.
Warnings and precautions
Serious Warnings and Precautions: Embryo-fetal toxicity: - Exposure to WELIREG® during pregnancy can cause embryo-fetal harm. - Verify pregnancy status prior to the initiation of WELIREG®. - Advise patients of these risks and the need for effective non-hormonal contraception. - WELIREG® can render hormonal contraceptives ineffective. Hypoxia: WELIREG® can cause severe hypoxia that may require discontinuation, supplemental oxygen, or hospitalization. Monitor oxygen saturation with pulse oximetry before initiation of and regularly at follow up visits throughout treatment. Some patients may experience asymptomatic hypoxia; at their discretion, health care providers may instruct patients to monitor oxygen saturation at home. Anemia: WELIREG® can cause severe anemia that can require blood transfusion and erythropoiesis stimulating agents. Monitor for anemia before initiation of and routinely throughout treatment. For patients who develop Grade 3 anemia, withhold WELIREG® and treat according to standard medical practice until resolved to ≤ Grade 2; then resume at the same or reduced dose. For recurrent Grade 3 anemia, consider discontinuing WELIREG®. For patients who develop Grade 4 anemia, withhold WELIREG®; then resume at a reduced dose or permanently discontinue for recurrent Grade 4 anemia.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
2 · Same class — other molecules in ATC L01XX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Arsenic Trioxide | ARSENIC TRIOXIDE FOR INJECTION · ARSENIC TRIOXIDE SOLUTION FOR INJECTION · TEVA-ARSENIC TRIOXIDE FOR INJECTION · TRISENOX | 10 | 4 | Yes |
| Hydroxycarbamide | APO-HYDROXYUREA · EUGIA-HYDROXYUREA · HYDREA · HYDROXYUREA · +2 more | 6 | 4 | Yes |
| Venetoclax | VENCLEXTA | 4 | 4 | Yes |
| Eribulin | ERIBULIN MESYLATE INJECTION · HALAVEN · NAT-ERIBULIN | 3 | 2 | Yes |
| Sotorasib | LUMAKRAS | 2 | 2 | Yes |
| Anagrelide | AGRYLIN · DOM-ANAGRELIDE · MYLAN-ANAGRELIDE · PHL-ANAGRELIDE · +2 more | 6 | 1 | Yes |
| Asparaginase | ERWINASE · KIDROLASE · RYLAZE | 3 | 1 | Yes |
| Pegaspargase | ONCASPAR | 2 | 1 | Yes |
| Belzutifan | WELIREG | 1 | 1 | Yes |
| Tebentafusp | KIMMTRAK | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L01X
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L01XG | Bortezomib · Carfilzomib · Ixazomib | 30 | 18 |
| L01XA | Carboplatin · Cisplatin · Oxaliplatin | 45 | 12 |
| L01XK | Niraparib · Niraparib And Abiraterone · Olaparib · Talazoparib | 12 | 7 |
| L01XL | Axicabtagene Ciloleucel · Brexucabtagene Autoleucel · Ciltacabtagene Autoleucel · Idecabtagene Vicleucel · Lifileucel · +2 more | 8 | 5 |
| L01XJ | Glasdegib · Sonidegib · Vismodegib | 4 | 4 |
| L01XD | Aminolevulinic Acid · Methyl Aminolevulinate · Porfimer Sodium | 5 | 3 |
| L01XH | Romidepsin · Vorinostat | 2 | 2 |
| L01XF | Tretinoin | 2 | 2 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is WELIREG called?
Also recorded in Canada as: belzutifan 40 MG Oral Tablet [Welireg] (US), belzutifan 40 MG Oral Tablet (US), BELZUTIFAN (US), BELZUTIFAN (GLOBAL), BELZUTIFAN (UK), MK-6482 (GLOBAL).
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.